A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus

Study Purpose

The goal of this clinical trial is to see how well cenerimod reduces symptoms of Systemic Lupus Erythematous in adult patients with moderate to severe symptoms. The main questions it aims to answer are:

  • - How well cenerimod works on top of the treatment already being administered.
  • - How safe cenerimod is for adult patients with Systemic Lupus Erythematosus.
Researchers will compare one dose of cenerimod and a placebo to see how well cenerimod works when it is added to the treatment already being administered. In this research study approximately 210 participants will receive cenerimod and approximately 210 participants will receive placebo for 12 months.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 18 Years - 75 Years
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

Inclusion criteria at screening:
  • - Signed Informed Consent Form (ICF) prior to any study-mandated procedure.
  • - Diagnosis of Systemic Lupus Erythematosus (SLE) made at least 6 months prior to Screening, according to 2019 European League Against Rheumatism / American College of Rheumatology Criteria.
  • - A modified Systemic Lupus Erythematosus Disease Activity Index-2000 (mSLEDAI-2K) score ≥ 6 and clinical mSLEDAI-2K score ≥ 4 with at least 2 points for musculoskeletal or mucocutaneous manifestations (i.e., myositis, arthritis, rash, alopecia, mucosal ulcers).
The mSLEDAI-2K score does not include "leukopenia".
  • - British Isles Lupus Assessment Group-2004 (BILAG) Grade B in ≥ 2 organ systems or a BILAG Grade A in ≥ 1 organ system.
  • - Physician's Global Assessment (PGA) score ≥ 1.0 on a 0 to 3 visual analog scale.
  • - Currently treated with one or more of the following SLE background medications: - Anti-malarials (≤ 400 mg/day hydroxychloroquine, ≤ 500 mg/day chloroquine, ≤ 100 mg/day quinacrine).
  • - Mycophenolate mofetil (≤ 2 g/day) / mycophenolic acid (≤1.44 g/day).
  • - Azathioprine (≤ 2 mg/kg/day).
  • - Methotrexate (≤ 25 mg/week).
  • - Oral Corticosteroids (OCS): - if OCS is the only SLE background medication: ≥ 7.5 mg/day and ≤ 30 mg/day prednisone or equivalent.
  • - if OCS is not the only SLE background medication: ≤ 30 mg/day prednisone or equivalent.
  • - Belimumab (≤10 mg/kg every 4 weeks intravenously [i.v.], or 200 mg/week subcutaneously [s.
c.]). Treatment with antimalarials, mycophenolate mofetil, mycophenolic acid, azathioprine, methotrexate or belimumab must have been started at least 90 days prior to Screening. Treatment with OCS must have been started at least 30 days prior to Screening. • For women of childbearing potential (WoCBP):
  • - Negative serum pregnancy test at Screening.
  • - Agreement to undertake monthly urine pregnancy tests from Randomization up to 6 months after study treatment discontinuation.
  • - Agreement to use a highly effective method of contraception from Screening (Visit 1) up to 6 months after study treatment discontinuation.
Inclusion criteria at randomization:
  • - A clinical mSLEDAI-2K score ≥ 4 with at least 2 points for musculoskeletal or mucocutaneous manifestations (i.e., myositis, arthritis, rash, alopecia, mucosal ulcers).
  • - BILAG Grade B in 2 or more organ systems or a BILAG Grade A in 1 or more organ system.
  • - PGA score ≥ 1.0 on a 0 to 3 visual analog scale.
  • - Presence of at least one of the following biomarkers of serological evidence of active SLE (in a Screening sample as measured by central laboratory): - Anti-dsDNA antibodies elevated above normal, - Antinuclear antibodies with a titer of at least 1:160, - Anti-Smith antibody elevated above normal.
  • - Currently treated with one or more of the following SLE background medications that must be stable for at least 30 days prior to Randomization (except OCS, which must be stable for at least 15 days prior to Randomization): - Antimalarials (≤ 400 mg/day hydroxychloroquine, ≤ 500 mg/day chloroquine, ≤ 100 mg/day quinacrine); - Mycophenolate mofetil (≤ 2 g/day) / mycophenolic acid (≤ 1.44g/day); - Azathioprine (≤ 2 mg/kg/day); - Methotrexate (≤ 25 mg/week); - OCS: - if OCS is the only SLE background medication: ≥ 7.5 mg/day and ≤ 30 mg/day prednisone or equivalent.
  • - if OCS is not the only SLE background medication: ≤ 30 mg/day prednisone or equivalent.
  • - Belimumab (≤ 10 mg/kg every 4 weeks i.v. or ≤ 200 mg/week s.
c.).
  • - WoCBP must have a negative urine pregnancy test at Randomization.
Main

Exclusion Criteria:

  • - Pregnant, planning to be become pregnant up to Final Study Visit, or lactating women.
  • - Severe active central nervous system lupus or active severe or unstable neuropsychiatric SLE including but not limited to: aseptic meningitis; cerebral vasculitis; myelopathy; demyelination syndromes (ascending, transverse, acute inflammatory demyelinating polyradiculopathy); acute confusional state; impaired level of consciousness; psychosis; acute stroke or stroke syndrome; cranial neuropathy; status epilepticus; cerebellar ataxia; or mononeuritis multiplex: - That would make the subject unable to fully understand the ICF; OR.
  • - Where, in the opinion of the investigator/delegate, protocol-specified standard of care is insufficient and the use of a more aggressive therapeutic approach, such as adding i.v. cyclophosphamide and/or high dose i.v. pulse corticosteroid (CS) therapy or other treatments not permitted in the protocol is indicated.
  • - A diagnosis of mixed connective tissue disease or any history of overlap syndromes of SLE with psoriasis, rheumatoid arthritis, erosive arthritis, scleroderma, autoimmune hepatitis or uncontrolled autoimmune thyroid disease.
  • - History or presence of Mobitz type II or third-degree atrioventricular block, sick sinus syndrome, symptomatic bradycardia or syncope associated with cardiac disorders.
  • - Subjects who experienced myocardial infarction, unstable angina pectoris, stroke, transient ischemic attack, vascular thrombosis, decompensated heart failure requiring hospitalization, or heart failure defined by the New York Heart Association Class III/IV within 6 months prior to Screening.
  • - Resting heart rate < 50 bpm as measured by the 12-lead ECG at Screening or at Randomization.
  • - An elevated QT interval corrected according to Fridericia's formula (QTcF) interval of > 470 ms (females) / > 450 ms (males) at Screening or at Randomization.
  • - History or presence of severe respiratory disease or pulmonary fibrosis, based on medical history, lung function, and chest X-ray (or CT scan as per local guidelines), performed at Screening or within 6 months prior to Screening.
  • - History of clinically relevant bronchial asthma or chronic obstructive pulmonary disease that has required treatment with oral or parenteral CS for more than a total of 2 weeks within the last 6 months prior to Screening.
  • - History or presence of malignancy (except for surgically excised and non-recurrent cutaneous basal cell carcinoma, squamous cell carcinoma, or cervical carcinoma), lymphoproliferative disease, or history of total lymphoid irradiation within 10 years prior to Screening.
  • - Presence of macular edema or active uveitis detected by optical coherence tomography (OCT) during screening.
  • - History of chronic liver or biliary disease (other than Gilbert's Syndrome) or subjects with alanine aminotransferase or aspartate aminotransferase > 3 × Upper Limit of Normal (ULN) or total bilirubin > 1.5 × ULN (unless in the context of known Gilbert's Syndrome).
  • - Significant hematology abnormality at screening assessment: - lymphocyte count < 500 /μL (0.5 × 10^9/L); - hemoglobin < 7 g/dL; - white blood cell count < 2000/μL (2.0 × 10^9/L); or.
  • - platelets < 25000/μL (25 × 10^9/L).
  • - Estimated glomerular filtration rate < 15 mL/min/1.73 m^2.
  • - Treatment with the following medications within 15 days or 5 half-lives of the medication (whichever is longer) prior to Randomization: - β-blockers, diltiazem, verapamil, digoxin, digitoxin, or any other antiarrhythmic or heart-rate -lowering systemic therapy.
  • - QT-prolonging drugs with known risk of torsade de pointes irrespective of indication.
  • - Treatment with the following medications within 30 days or 5 half-lives of the medication (whichever is longer) prior to Randomization: - Cyclophosphamide, cyclosporine, voclosporin, tacrolimus, sirolimus, etc. - Pulse methylprednisolone.
  • - Vaccination with live vaccines (including live vaccines for COVID-19).
  • - Intra-articular, intramuscular or i.v. CS within 6 weeks prior to Randomization.
  • - Treatment with the following medications within 90 days or 5 half-lives of the medication (whichever is longer) prior to Randomization: - Leflunomide.
  • - i.v. immunoglobulins.
  • - Treatment with any investigational agent within 90 days or 5 half-lives of the drug (whichever is longer) prior to Randomization.
  • - Treatment with B cell-depleting biological agents (e.g., rituximab or ocrelizumab) or biological immunosuppressive agents (e.g., anti-tumor necrosis factor [TNF], anti-interleukin [IL]-1, anti-IL6 therapies), within 12 months prior to Randomization.
  • - Treatment with anifrolumab within 6 months prior to Randomization.
  • - Treatment with any of the following medications any time prior to Screening: - Alemtuzumab, - Sphingosine-1-phosphate receptor modulators (e.g., fingolimod), - Subjects previously randomized to cenerimod or placebo in any trial involving cenerimod.

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT05672576
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 3
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Idorsia Pharmaceuticals Ltd.
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Clinical Trials
Principal Investigator Affiliation Idorsia Pharmaceuticals Ltd.
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Industry
Overall Status Recruiting
Countries Chile, Czechia, Georgia, Germany, Japan, Mexico, Peru, Philippines, Poland, Portugal, Puerto Rico, Serbia, South Africa, Spain, United States
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Lupus Erythematosus, Systemic
Arms & Interventions

Arms

Experimental: Cenerimod 4 mg

Participants will receive cenerimod once daily in addition to background SLE therapy.

Placebo Comparator: Placebo

Participants will receive matching placebo once daily in addition to background SLE therapy.

Interventions

Drug: - Cenerimod

Cenerimod will be supplied as film-coated tablets at the dose of 4 mg.

Drug: - Placebo

Matching placebo will be supplied as identical film-coated tablets formulated with the same excipients but without the active ingredient, cenerimod.

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

UCSD Perlman Medical Offices, La Jolla, California

Status

Recruiting

Address

UCSD Perlman Medical Offices

La Jolla, California, 92037-0943

Riverside, California

Status

Recruiting

Address

Arthritis Medical Clinic Osteoporosis Diagnostic Imaging and Treatment Center

Riverside, California, 92506

Hope Clinical Trials, Inc., Coral Gables, Florida

Status

Recruiting

Address

Hope Clinical Trials, Inc.

Coral Gables, Florida, 33134

Vital Pharma Research, Hialeah, Florida

Status

Recruiting

Address

Vital Pharma Research

Hialeah, Florida, 33016

San Marcus Research Clinic, Inc., Miami Lakes, Florida

Status

Recruiting

Address

San Marcus Research Clinic, Inc.

Miami Lakes, Florida, 33014

D&H National Research Centers INC, Miami, Florida

Status

Recruiting

Address

D&H National Research Centers INC

Miami, Florida, 33155

Integrity Trials LLC, Orlando, Florida

Status

Withdrawn

Address

Integrity Trials LLC

Orlando, Florida, 32822

D&H Tamarac Research Center, Tamarac, Florida

Status

Withdrawn

Address

D&H Tamarac Research Center

Tamarac, Florida, 33321

Tandem Clinical Research, Marrero, Louisiana

Status

Recruiting

Address

Tandem Clinical Research

Marrero, Louisiana, 70072

Saint Paul Rheumatology, P.A., Eagan, Minnesota

Status

Withdrawn

Address

Saint Paul Rheumatology, P.A.

Eagan, Minnesota, 55121

IMA Clinical Research Las Vegas, Las Vegas, Nevada

Status

Withdrawn

Address

IMA Clinical Research Las Vegas

Las Vegas, Nevada, 891002

Columbia University Medical Center, New York, New York

Status

Recruiting

Address

Columbia University Medical Center

New York, New York, 10032

Accellacare Research of Cary, Cary, North Carolina

Status

Not yet recruiting

Address

Accellacare Research of Cary

Cary, North Carolina, 27518

Duncansville, Pennsylvania

Status

Withdrawn

Address

Altoona Center for Clinical Research Department of Rheumatology

Duncansville, Pennsylvania, 16635

Texas Arthritis Center, El Paso, Texas

Status

Not yet recruiting

Address

Texas Arthritis Center

El Paso, Texas, 79902

Northwest Houston Arthritis Center, Houston, Texas

Status

Recruiting

Address

Northwest Houston Arthritis Center

Houston, Texas, 77090

International Sites

Biomedica Research Group, Providencia, Chile

Status

Recruiting

Address

Biomedica Research Group

Providencia, , 7500710

PROSALUD, Providencia, Chile

Status

Withdrawn

Address

PROSALUD

Providencia, , 7510047

Providencia, Chile

Status

Recruiting

Address

Sociedad Médica del Aparato Locomotor S. A.

Providencia, , 7510186

Enroll SpA, Santiago, Chile

Status

Recruiting

Address

Enroll SpA

Santiago, , 7500587

Clinical Research Chile SpA, Valdivia, Chile

Status

Recruiting

Address

Clinical Research Chile SpA

Valdivia, , 5110683

Hospital San José de Victoria, Victoria, Chile

Status

Recruiting

Address

Hospital San José de Victoria

Victoria, , 4720001

iMedica s.r.o., Brno, Czechia

Status

Recruiting

Address

iMedica s.r.o.

Brno, , 60200

Institute of Rheumatology Prague, Praha 2, Czechia

Status

Recruiting

Address

Institute of Rheumatology Prague

Praha 2, , 12800

LTD "New Plasma Clinic", Batumi, Georgia

Status

Recruiting

Address

LTD "New Plasma Clinic"

Batumi, , 6010

Institute of Clinical Cardiology, Ltd, Tbilisi, Georgia

Status

Recruiting

Address

Institute of Clinical Cardiology, Ltd

Tbilisi, , 0159

LTD "Tbilisi Central Hospital", Tbilisi, Georgia

Status

Recruiting

Address

LTD "Tbilisi Central Hospital"

Tbilisi, , 0159

National Institute of Endocrinology Ltd., Tbilisi, Georgia

Status

Recruiting

Address

National Institute of Endocrinology Ltd.

Tbilisi, , 0159

Tbilisi Heart and Vascular Clinic Ltd., Tbilisi, Georgia

Status

Recruiting

Address

Tbilisi Heart and Vascular Clinic Ltd.

Tbilisi, , 0159

Aversi Clinic LTD, Tbilisi, Georgia

Status

Recruiting

Address

Aversi Clinic LTD

Tbilisi, , 0160

Medi Club Georgia Ltd., Tbilisi, Georgia

Status

Recruiting

Address

Medi Club Georgia Ltd.

Tbilisi, , 0160

Ltd. Mtskheta Street Clinic, Tbilisi, Georgia

Status

Recruiting

Address

Ltd. Mtskheta Street Clinic

Tbilisi, , 0179

The First Medical Center Ltd., Tbilisi, Georgia

Status

Recruiting

Address

The First Medical Center Ltd.

Tbilisi, , 0180

LLC "Innova", Tbilisi, Georgia

Status

Recruiting

Address

LLC "Innova"

Tbilisi, , 0186

LLC Raymann, Tbilisi, Georgia

Status

Recruiting

Address

LLC Raymann

Tbilisi, , 0186

LTD "Tbilisi Heart Center", Tbilisi, Georgia

Status

Recruiting

Address

LTD "Tbilisi Heart Center"

Tbilisi, , 0186

Frankfurt am Main, Germany

Status

Recruiting

Address

Fraunhofer-Institut für Translationale Medizin und Pharmakologie ITMP

Frankfurt am Main, , 60596

Städtisches Klinikum Karlsruhe gGmbH, Karlsruhe, Germany

Status

Recruiting

Address

Städtisches Klinikum Karlsruhe gGmbH

Karlsruhe, , 76133

Universitätsklinikum Leipzig, Leipzig, Germany

Status

Recruiting

Address

Universitätsklinikum Leipzig

Leipzig, , 4103

Johannes Wesling Klinikum Minden, Minden, Germany

Status

Recruiting

Address

Johannes Wesling Klinikum Minden

Minden, , 32429

Universitätsklinikum Münster (UKM), Münster, Germany

Status

Recruiting

Address

Universitätsklinikum Münster (UKM)

Münster, , 48149

Iizuka Hospital, Iizuka City, Japan

Status

Withdrawn

Address

Iizuka Hospital

Iizuka City, , 820-8505

Nagasaki University Hospital, Nagasaki-shi, Japan

Status

Withdrawn

Address

Nagasaki University Hospital

Nagasaki-shi, , 852-8501

Chukyo Hospital, Nagoya-shi, Japan

Status

Withdrawn

Address

Chukyo Hospital

Nagoya-shi, , 457-8510

Nagoya City University Hospital, Nagoya-shi, Japan

Status

Withdrawn

Address

Nagoya City University Hospital

Nagoya-shi, , 467-8602

Shinkenko Clinic, Naha-shi, Japan

Status

Withdrawn

Address

Shinkenko Clinic

Naha-shi, , 900-0015

Tomakomai City Hospital, Tomakomai-shi, Japan

Status

Withdrawn

Address

Tomakomai City Hospital

Tomakomai-shi, , 053-0034

Juntendo University Urayasu Hospital, Urayasu, Japan

Status

Withdrawn

Address

Juntendo University Urayasu Hospital

Urayasu, , 279-0021

Ciudad de México, Mexico

Status

Not yet recruiting

Address

Centro de Investigación Clínica GRAMEL, S.C.

Ciudad de México, , 03720

Clinstile, S.A. de C.V., Ciudad de México, Mexico

Status

Not yet recruiting

Address

Clinstile, S.A. de C.V.

Ciudad de México, , 06700

Cuernavaca, Mexico

Status

Not yet recruiting

Address

Consultorio Particular Dr. Miguel Cortés Hernández

Cuernavaca, , 62448

Guadalajara, Mexico

Status

Not yet recruiting

Address

Centro Integral en Reumatologia SA de CV (CIRSA)

Guadalajara, , 44160

León, Mexico

Status

Not yet recruiting

Address

Morales Vargas Centro de Investigación S.C.

León, , 37000

Merida, Mexico

Status

Not yet recruiting

Address

Centro Multidisciplinario para el Desarrollo Especializado de la Investigacion Clinica en Yucatan S.C.P. (CEMDEICY S.C.P.)

Merida, , 97130

Boca Clinical Trials Mexico, S.C., Mexico City, Mexico

Status

Not yet recruiting

Address

Boca Clinical Trials Mexico, S.C.

Mexico City, , 01120

Accelerium, S. de R.L. de C.V., Monterrey, Mexico

Status

Not yet recruiting

Address

Accelerium, S. de R.L. de C.V.

Monterrey, , 64000

UBAM Unidad Biomédica Avanzada Monterrey, Monterrey, Mexico

Status

Not yet recruiting

Address

UBAM Unidad Biomédica Avanzada Monterrey

Monterrey, , 64460

Oaxaca contra el Cáncer A.C, Oaxaca de Juárez, Mexico

Status

Not yet recruiting

Address

Oaxaca contra el Cáncer A.C

Oaxaca de Juárez, , 68000

Querétaro, Mexico

Status

Not yet recruiting

Address

Centro de Estudios Clínicos de Querétaro S.C.

Querétaro, , 76000

Clinical Research Institute S.C., Tlanepantla de Baz, Mexico

Status

Not yet recruiting

Address

Clinical Research Institute S.C.

Tlanepantla de Baz, , 54055

PCR Toluca - Phylasis Clinical Research, Toluca de Lerdo, Mexico

Status

Not yet recruiting

Address

PCR Toluca - Phylasis Clinical Research

Toluca de Lerdo, , 50090

Cayma, Peru

Status

Not yet recruiting

Address

Unidad de Investigación en Medicina Interna y Enfermedades Críticas / Hogar Clínica San Juan de Dios

Cayma, , 04017

Jesús María, Peru

Status

Not yet recruiting

Address

Centro de Investigacion Clinica Inmunoreumatologia / ACQ Medic SAC

Jesús María, , 15076

Jesús María, Peru

Status

Recruiting

Address

Centro de Investigación del Hospital Militar Central

Jesús María, , 15076

Lima, Peru

Status

Recruiting

Address

Alberto Sabogal Sologuren National Hospital

Lima, , 07011

Hospital Maria Auxiliadora, Lima, Peru

Status

Recruiting

Address

Hospital Maria Auxiliadora

Lima, , 15828

San Borja, Peru

Status

Recruiting

Address

Unidad de Investigación de la Clinica International

San Borja, , 15036

San Isidro, Peru

Status

Recruiting

Address

Instituto Peruano del Hueso y la Articulación S.A.C. (IPHAR)

San Isidro, , 15046

Clínica Anglo Americana, San Isidro, Peru

Status

Recruiting

Address

Clínica Anglo Americana

San Isidro, , 15073

San Isidro, Peru

Status

Recruiting

Address

Servicios Reumatológicos SOMA E.I.R.L. / Clinica El Golf

San Isidro, , 15076

San Juan de Lurigancho, Peru

Status

Recruiting

Address

Unidad de Investigación en Reumatología e Inmunología CSJB

San Juan de Lurigancho, , 15431

Hospital Nacional Cayetano Heredia, San Martín de Porres, Peru

Status

Recruiting

Address

Hospital Nacional Cayetano Heredia

San Martín de Porres, , 15102

Santiago De Surco, Peru

Status

Recruiting

Address

Investigaciones Clinicas / Instituto de Ginecología y Reproducción, El Derby

Santiago De Surco, , 15023

Trujillo, Peru

Status

Recruiting

Address

Centro de Investigación Clínica Trujillo EIRL / Clínica Peruano Americana S.A

Trujillo, , 13011

Iloilo Doctors Hospital, Iloilo City, Philippines

Status

Recruiting

Address

Iloilo Doctors Hospital

Iloilo City, , 5000

Makati Medical Center, Makati, Philippines

Status

Recruiting

Address

Makati Medical Center

Makati, , 1229

St Lukes Medical Center, Manila, Philippines

Status

Recruiting

Address

St Lukes Medical Center

Manila, , 1102

Sampaloc, Philippines

Status

Recruiting

Address

St Luke's Medical Center Quezon City / University of Santo Tomas Hospital

Sampaloc, , 1015

Bydgoszcz, Poland

Status

Recruiting

Address

Szpital Uniwersytecki nr 2 im. dr. Jana Biziela w Bydgoszczy

Bydgoszcz, , 85-168

Medyczne Centrum Hetmańska, Poznań, Poland

Status

Recruiting

Address

Medyczne Centrum Hetmańska

Poznań, , 60-218

Poznań, Poland

Status

Recruiting

Address

Twoja Przychodnia Poznańskie Centrum Medyczne

Poznań, , 61-293

Szczecin, Poland

Status

Recruiting

Address

Pomorski Uniwersytet Medyczny w Szczecinie

Szczecin, , 71-252

MICS Centrum Medyczne Warszawa, Warszawa, Poland

Status

Recruiting

Address

MICS Centrum Medyczne Warszawa

Warszawa, , 00-874

Hospital Prof. Doutor Fernando Fonseca, Amadora, Portugal

Status

Recruiting

Address

Hospital Prof. Doutor Fernando Fonseca

Amadora, , 2720-276

Faro, Portugal

Status

Recruiting

Address

Centro Hospitalar Universitário do Algarve - Hospital de Faro

Faro, , 8000-386

ULS Guarda, Guarda, Portugal

Status

Recruiting

Address

ULS Guarda

Guarda, , 6300-749

Hospital Senhora Oliveira-Guimaraes, Guimarães, Portugal

Status

Recruiting

Address

Hospital Senhora Oliveira-Guimaraes

Guimarães, , 4835-044

Instituto Portugues De Reumatologia, Lisbon, Portugal

Status

Recruiting

Address

Instituto Portugues De Reumatologia

Lisbon, , 1050-034

Vila Nova de Gaia, Portugal

Status

Recruiting

Address

Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E.

Vila Nova de Gaia, , 4434-502

Centro Reumatologico de Caguas, Caguas, Puerto Rico

Status

Recruiting

Address

Centro Reumatologico de Caguas

Caguas, , 00725

GCM Medical Group, PSC, San Juan, Puerto Rico

Status

Recruiting

Address

GCM Medical Group, PSC

San Juan, , 917

Belgrade, Serbia

Status

Recruiting

Address

Institute of Rheumatology, Belgrade (study site 1)

Belgrade, , 11000

Belgrade, Serbia

Status

Recruiting

Address

Institute of Rheumatology, Belgrade (study site 2)

Belgrade, , 11000

Belgrade, Serbia

Status

Recruiting

Address

Institute of Rheumatology, Belgrade (study site 3)

Belgrade, , 11000

University Clinical Center of Serbia, Belgrade, Serbia

Status

Recruiting

Address

University Clinical Center of Serbia

Belgrade, , 11000

Military Medical Academy, Belgrade, Serbia

Status

Recruiting

Address

Military Medical Academy

Belgrade, , 11040

Clinical Center Kragujevac, Kragujevac, Serbia

Status

Not yet recruiting

Address

Clinical Center Kragujevac

Kragujevac, , 34000

Novi Sad, Serbia

Status

Recruiting

Address

Special Hospital for Rheumatic Diseases, Novi Sad

Novi Sad, , 21000

General Hospital "Djordje Joanovic", Zrenjanin, Serbia

Status

Recruiting

Address

General Hospital "Djordje Joanovic"

Zrenjanin, , 23000

Arthritis Clinical Research Trials, Cape Town, South Africa

Status

Recruiting

Address

Arthritis Clinical Research Trials

Cape Town, , 7405

Panorama Medical Centre, Cape Town, South Africa

Status

Recruiting

Address

Panorama Medical Centre

Cape Town, , 7500

Parktown, South Africa

Status

Recruiting

Address

Charlotte Maxeke Johannesburg Academic Hospital

Parktown, , 2193

University of Pretoria, Pretoria, South Africa

Status

Recruiting

Address

University of Pretoria

Pretoria, , 0002

Winelands Medical Research, Somerset West, South Africa

Status

Recruiting

Address

Winelands Medical Research

Somerset West, , 7130

Parc Tauli Sabadell University Hospital, Barcelona, Spain

Status

Recruiting

Address

Parc Tauli Sabadell University Hospital

Barcelona, , 08208

Clinica Gaias Santiago, Santiago De Compostela, Spain

Status

Recruiting

Address

Clinica Gaias Santiago

Santiago De Compostela, , 15702

Hospital QuironSalud Sagrado Corazon, Sevilla, Spain

Status

Recruiting

Address

Hospital QuironSalud Sagrado Corazon

Sevilla, , 41013

Valencia, Spain

Status

Recruiting

Address

Hospital Clinico Universitario de Valencia

Valencia, , 46010

Hospital Universitario Doctor Peset, Valencia, Spain

Status

Recruiting

Address

Hospital Universitario Doctor Peset

Valencia, , 46017

Valladolid, Spain

Status

Recruiting

Address

Hospital Universitario Río Hortega de Valladolid

Valladolid, , 47012